IGF-1 LR3
Lyophilized research reference material. Released with a per-lot Certificate of Analysis. For laboratory research use only.
- All products currently listed on this site are for research purposes ONLY.
- All products sold on this website are intended for research and identification purposes only.
- These products are not intended for human dosing, injections, or ingestion.
- Peptides are strictly for laboratory, academic, or institutional research and not for human or animal consumption.
Research background
IGF-1 LR3 (Long R3 insulin-like growth factor-1) is an 83-amino-acid recombinant analog of human IGF-1, bearing an Arg substitution at position 3 and a 13-residue N-terminal extension. These modifications reduce binding to IGF-binding proteins, increasing free availability of the molecule in research systems.
It is widely used as a cell-culture reagent and research analog; it has no approved clinical indication.
Summary of published scientific literature provided for laboratory research reference only. It is not a claim of safety, efficacy, or suitability for any use, and does not describe or recommend any human or veterinary use.
Selected references
- Tomas FM, et al. Long-R3-IGF-I increases protein deposition and reduces protein degradation. Journal of Endocrinology. 1993;137(3):413-421.
- Francis GL, et al. Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and analogue design. Biochemical Journal. 1993;293(3):713-719.
- Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders. Nature Reviews Drug Discovery. 2007;6(10):821-833.
Trademarks & attribution
IGF-1 LR3 is a recombinant research analog of human IGF-1 with no approved trademarked drug product. Catalyst Research Labs is not affiliated with any manufacturer. Supplied as reference material only.
